We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
- Authors
Baselga, José; Semiglazov, Vladimir; van Dam, Peter; Manikhas, Alexey; Bellet, Meritxell; Mayordomo, José; Campone, Mario; Kubista, Ernst; Greil, Richard; Bianchi, Giulia; Steinseifer, Jutta; Molloy, Betty; Tokaji, Erika; Gardner, Humphrey; Phillips, Penny; Stumm, Michael; Lane, Heidi A; Dixon, J Michael; Jonat, Walter; Rugo, Hope S
- Abstract
Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and blockade of both pathways enhances antitumor activity in preclinical models. This study explored whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 16, p2630
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.18.8391